Meanwhile, other studies suggested that a higher α-diversity in the stool microbiome could be associated with higher PD-L1 expression levels, better responses, and prolonged progression-free survival in NSCLC patients treated with immunotherapy [75,77]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.